ATE504653T1 - Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren - Google Patents

Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren

Info

Publication number
ATE504653T1
ATE504653T1 AT03784104T AT03784104T ATE504653T1 AT E504653 T1 ATE504653 T1 AT E504653T1 AT 03784104 T AT03784104 T AT 03784104T AT 03784104 T AT03784104 T AT 03784104T AT E504653 T1 ATE504653 T1 AT E504653T1
Authority
AT
Austria
Prior art keywords
vaccinia virus
avipoxviruses
host range
increasing
cells
Prior art date
Application number
AT03784104T
Other languages
English (en)
Inventor
Paul Howley
Christine Meisinger-Henschel
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of ATE504653T1 publication Critical patent/ATE504653T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03784104T 2002-08-07 2003-07-29 Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren ATE504653T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200201189 2002-08-07
PCT/EP2003/008359 WO2004015118A1 (en) 2002-08-07 2003-07-29 Vaccinia virus host range genes to increase the titer of avipoxviruses

Publications (1)

Publication Number Publication Date
ATE504653T1 true ATE504653T1 (de) 2011-04-15

Family

ID=31502636

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03784104T ATE504653T1 (de) 2002-08-07 2003-07-29 Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren

Country Status (8)

Country Link
US (2) US7473536B2 (de)
EP (2) EP2264178A1 (de)
JP (1) JP2005534326A (de)
AT (1) ATE504653T1 (de)
AU (1) AU2003255315A1 (de)
CA (1) CA2489301A1 (de)
DE (1) DE60336653D1 (de)
WO (1) WO2004015118A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
US7473536B2 (en) * 2002-08-07 2009-01-06 Bavarian Nordic A/S Isolated avian cell that expresses Vaccinia virus host range genes
EP1528101A1 (de) 2003-11-03 2005-05-04 ProBioGen AG Immortalisierte Vogel-Zelllinien für die Produktion von Viren
EP1845164B1 (de) * 2003-11-24 2010-06-16 Bavarian Nordic A/S Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
ES2315096B1 (es) * 2006-05-13 2009-12-30 Consejo Superior De Investigaciones Cientificas Vectores en los que se inserta el gen c7l y uso de los mismos en la fabricacion de vacunas y de composiciones para terapia genica.
US20090060947A1 (en) * 2006-05-19 2009-03-05 Sanofi Pasteur, Inc. Immunological compositions
US9670506B2 (en) 2009-04-30 2017-06-06 Consejo Superior De Investigaciones Cientificas Modified immunization vectors
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
HUE037718T2 (hu) * 2013-11-01 2018-09-28 Sementis Ltd Virális vektor elõállítása
US20210301263A1 (en) * 2018-08-08 2021-09-30 Arizona Board Of Regents On Behalf Of Arizona State University Methods for improved poxvirus yields
WO2023277069A1 (ja) * 2021-06-30 2023-01-05 株式会社レプリテック マイナス鎖ｒｎａウイルスベクターの製造方法および製造されたマイナス鎖ｒｎａウイルスベクター

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
AU570940B2 (en) 1982-11-30 1988-03-31 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for producing poxvirus recombinants for expression offoreign genes
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
WO1992015672A1 (en) * 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
ID19548A (id) 1996-09-24 1998-07-23 Bavarian Nordic Res Inst As Virus mva rekombinan yang mengekspresikan antigen-antigen virus demam dan penggunaan daripadanya dalam vaksin-vaksin
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6004777A (en) * 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6294176B1 (en) * 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
FR2811766B1 (fr) 2000-07-13 2002-09-27 Tabacs & Allumettes Ind Procede de caracterisation de la compacite d'objets tels que des cigarettes ou des filtres
AU2002246829A1 (en) * 2000-12-22 2002-07-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health A Methods to control the host range of retroviral vectors
US7473536B2 (en) * 2002-08-07 2009-01-06 Bavarian Nordic A/S Isolated avian cell that expresses Vaccinia virus host range genes

Also Published As

Publication number Publication date
CA2489301A1 (en) 2004-02-19
JP2005534326A (ja) 2005-11-17
US20060039928A1 (en) 2006-02-23
US20090162935A1 (en) 2009-06-25
WO2004015118A1 (en) 2004-02-19
EP1529113B1 (de) 2011-04-06
AU2003255315A1 (en) 2004-02-25
DE60336653D1 (de) 2011-05-19
EP1529113A1 (de) 2005-05-11
US7473536B2 (en) 2009-01-06
EP2264178A1 (de) 2010-12-22

Similar Documents

Publication Publication Date Title
ATE504653T1 (de) Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
DK0702085T3 (da) Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
WO2000003030A3 (en) Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
EA200201164A1 (ru) Система трансфекции днк для получения инфекционного вируса гриппа
CY1114598T1 (el) Μεθοδος για την ενισχυση ενος ιου φυσαλιδωδους νοσου υπο συνθηκες ελευθερες ορου
WO2006136448A3 (en) Attenuated sars and use as a vaccine
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
NO20032309L (no) Modifisert variant av vaccinia ankaravirus
WO2001039797A3 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
ATE507293T1 (de) Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
HK1076835A1 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
WO2003023040A3 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
MX2007009628A (es) Virus de acido ribonucleico en replicacion como vacunas.
AU7411694A (en) Viruses and their use as a vaccine against feline infectious peritonitis virus disease
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
WO2003106641A3 (en) IDENTIFICATION OF OLIGONUCLEOTIDES FOR CAPTURE, DETECTION AND QUANTIFICATION OF NUCLEIC ACIDS FROM HEPATITIS A VIRUS
WO2003031934A3 (en) Identification of oligonucleotides for the capture, detection and quantitation of hepatitis b viral dna
DK1356062T3 (da) Frembringelse af rekombinanter af kunstigt gærkromosom af human cytomegalovirus
JP2005534326A5 (de)
EA200601218A1 (ru) Респираторно-синцитиальный вирус с перекрёстно компенсированным геномным дефицитом
WO2007038316A3 (en) Human cytomegalovirus latency promoting genes, related virus variants and methods of use
WO2000043520A3 (en) Materials and methods for producing geminivirus resistant plants
HUP0103871A2 (hu) Rekombináns CELO-vírus és CELO vírus DNS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties